HRP20110899T1 - Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ - Google Patents
Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ Download PDFInfo
- Publication number
- HRP20110899T1 HRP20110899T1 HR20110899T HRP20110899T HRP20110899T1 HR P20110899 T1 HRP20110899 T1 HR P20110899T1 HR 20110899 T HR20110899 T HR 20110899T HR P20110899 T HRP20110899 T HR P20110899T HR P20110899 T1 HRP20110899 T1 HR P20110899T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- lymphocytes
- cells
- antigen
- antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110899T1 true HRP20110899T1 (hr) | 2011-12-31 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110899T HRP20110899T1 (hr) | 2007-01-03 | 2008-01-03 | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (https=) |
| EP (1) | EP2102331B1 (https=) |
| JP (1) | JP5452231B2 (https=) |
| AT (1) | ATE522600T1 (https=) |
| AU (1) | AU2008203730B2 (https=) |
| CY (1) | CY1112668T1 (https=) |
| DK (1) | DK2102331T3 (https=) |
| ES (1) | ES2372713T3 (https=) |
| GB (1) | GB0700058D0 (https=) |
| HR (1) | HRP20110899T1 (https=) |
| PL (1) | PL2102331T3 (https=) |
| PT (1) | PT2102331E (https=) |
| SI (1) | SI2102331T1 (https=) |
| WO (1) | WO2008081035A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801751A1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8467973B2 (en) * | 2009-07-28 | 2013-06-18 | Promising Future, Llc | Pairing processes for preparing alloreactive cytotoxic T cells |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| JP5816627B2 (ja) * | 2009-10-27 | 2015-11-18 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| MX388325B (es) | 2015-05-28 | 2025-03-19 | Kite Pharma Inc | Metodos de diagnostico para tratamiento con linfocitos t. |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| EP3364969A4 (en) | 2015-10-20 | 2019-07-10 | Kite Pharma, Inc. | METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY |
| CN109414455B (zh) | 2016-04-01 | 2023-01-20 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| KR20200068750A (ko) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| PT3436079T (pt) | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
| PT3583129T (pt) | 2017-02-14 | 2021-12-14 | Kite Pharma Inc | Moléculas de ligação a cd70 e seus métodos de uso |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| EP3490605B1 (en) | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| AU2018250148B2 (en) | 2017-04-03 | 2021-09-23 | Kite Pharma, Inc. | Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells |
| SG10201912400VA (en) | 2017-04-24 | 2020-02-27 | Kite Pharma Inc | Humanized antigen-binding domains against cd19 and methods of use |
| TWI862477B (zh) | 2017-05-26 | 2024-11-21 | 美商凱特製藥公司 | 製備和使用胚胎間充質先驅細胞的方法 |
| KR20230052312A (ko) | 2017-09-15 | 2023-04-19 | 카이트 파마 인코포레이티드 | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 |
| CA3076099A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Linkers for chimeric antigen receptors |
| CA3084470A1 (en) | 2017-10-18 | 2019-04-25 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| BR112020014446A2 (pt) | 2018-01-15 | 2020-12-29 | Pfizer Inc. | Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb |
| WO2019152957A1 (en) | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| CN112534044A (zh) | 2018-02-16 | 2021-03-19 | 凯德药业股份有限公司 | 经修饰的多能干细胞及制备和使用方法 |
| TWI784324B (zh) | 2018-04-12 | 2022-11-21 | 美商凱特製藥公司 | 利用腫瘤微環境之特性之嵌合受體t細胞治療 |
| KR102544086B1 (ko) | 2018-06-01 | 2023-06-16 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| US20210155941A1 (en) | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| SG11202101014XA (en) | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| KR102840400B1 (ko) | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| US20220175900A1 (en) * | 2019-04-12 | 2022-06-09 | Cytovac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| US20200384027A1 (en) | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| KR20220054383A (ko) | 2019-09-03 | 2022-05-02 | 알로젠 테라퓨틱스 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| IL292665B2 (en) | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| US12152251B2 (en) | 2020-08-25 | 2024-11-26 | Kite Pharma, Inc. | T cells with improved functionality |
| US20220155299A1 (en) | 2020-10-28 | 2022-05-19 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| AU2021410635A1 (en) | 2020-12-24 | 2023-06-29 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
| WO2022150582A1 (en) | 2021-01-10 | 2022-07-14 | Kite Pharma, Inc. | T cell therapy |
| EP4281545A1 (en) | 2021-01-21 | 2023-11-29 | CytoVac A/S | Method for t-cell expansion and related medical applications |
| TW202241469A (zh) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| IL305571A (en) | 2021-03-11 | 2023-10-01 | Kite Pharma Inc | Improving the function of immune system cells |
| AU2022259428A1 (en) | 2021-04-16 | 2023-10-26 | Kite Pharma, Inc. | Taci/bcma dual binding molecules |
| WO2022221126A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| EP4337227A2 (en) | 2021-05-14 | 2024-03-20 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| IL308696A (en) | 2021-05-24 | 2024-01-01 | Kite Pharma Inc | Nkg2d-based chimeric antgen receptor |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| JP2024525485A (ja) | 2021-07-02 | 2024-07-12 | カイト ファーマ インコーポレイテッド | 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法 |
| WO2023009989A1 (en) | 2021-07-26 | 2023-02-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| US20230268031A1 (en) | 2021-07-30 | 2023-08-24 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
| TWI863006B (zh) | 2021-10-18 | 2024-11-21 | 美商凱特製藥公司 | 用於嵌合抗原受體之信號傳導域 |
| US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| KR20250097844A (ko) | 2022-10-28 | 2025-06-30 | 카이트 파마 인코포레이티드 | 면역요법의 효능 향상 및 지속적인 반응 |
| WO2024092227A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
| KR20250162836A (ko) | 2023-03-17 | 2025-11-19 | 카이트 파마 인코포레이티드 | 종양 미세환경이 면역요법의 효능에 미치는 영향 |
| WO2025096517A1 (en) | 2023-11-01 | 2025-05-08 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| US20250262300A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| WO2025188561A1 (en) | 2024-03-04 | 2025-09-12 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| WO2025231376A1 (en) | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Chimeric receptors binding to cll-1 and methods of use thereof |
| WO2025250819A1 (en) | 2024-05-31 | 2025-12-04 | Kite Pharma, Inc. | Tricistronic constructs for anti-gpc3 car |
| US20260009001A1 (en) | 2024-07-08 | 2026-01-08 | Kite Pharma, Inc. | Systems and methods for applying mechanical force to living cells to generate a phenotypic response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en not_active Ceased
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5452231B2 (ja) | 2014-03-26 |
| US10023839B2 (en) | 2018-07-17 |
| PT2102331E (pt) | 2011-12-19 |
| WO2008081035A1 (en) | 2008-07-10 |
| US20180036397A1 (en) | 2018-02-08 |
| CY1112668T1 (el) | 2016-02-10 |
| PL2102331T3 (pl) | 2012-01-31 |
| AU2008203730B2 (en) | 2013-11-07 |
| EP2102331A1 (en) | 2009-09-23 |
| DK2102331T3 (da) | 2011-10-17 |
| AU2008203730A1 (en) | 2008-07-10 |
| JP2010514455A (ja) | 2010-05-06 |
| SI2102331T1 (sl) | 2012-01-31 |
| EP2102331B1 (en) | 2011-08-31 |
| ATE522600T1 (de) | 2011-09-15 |
| GB0700058D0 (en) | 2007-02-07 |
| ES2372713T3 (es) | 2012-01-25 |
| US20100092498A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110899T1 (hr) | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ | |
| JP2010514455A5 (https=) | ||
| Banchereau et al. | Dendritic cells as therapeutic vaccines against cancer | |
| EP2494038B1 (en) | Method for proliferation of antigen-specific t cells | |
| Galluzzi et al. | Trial watch: Dendritic cell-based interventions for cancer therapy | |
| Wennhold et al. | CD40-activated B cells induce anti-tumor immunity in vivo | |
| ES2601896T3 (es) | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales | |
| Vacchelli et al. | Trial watch: Peptide vaccines in cancer therapy | |
| Du et al. | Hypothermic microenvironment plays a key role in tumor immune subversion | |
| IL273452B2 (en) | Cell preparations comprising antigen-specific T cells for adoptive therapy | |
| Abraham et al. | Gene-modified dendritic cell vaccines for cancer | |
| Huarte et al. | Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma | |
| Cao et al. | Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma | |
| Millard et al. | Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines | |
| Shao et al. | Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy | |
| RU2728592C1 (ru) | Способ стимуляции презентирующей активности дендритных клеток | |
| Saha et al. | Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell‐based immunotherapy of colon cancer in CEA/HLA‐A2 transgenic mice | |
| He et al. | Antigen epitope-expressing cytokines for DNA immunization | |
| Jeon | Role of toll-like receptor agonists as cancer vaccine adjuvants | |
| Yun et al. | Generation of antigen-specific cytotoxic T lymphocytes with activated B cells | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
| WO2017139742A1 (en) | Placental compositions for stimulation of immunity to pd-l1 | |
| CN111518216A (zh) | 多肽、含有多肽的组合物及其在肿瘤免疫中的应用 | |
| Mann et al. | Investigation of cellular and humoral immune responses to tumor-associated antigens and survival of patients with advanced cancers treated with combined radiation and immunotherapy | |
| Sun et al. | Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model |